Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | THRB | P10828 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.49 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173304 | 0.87 | POLB (0.68) | TP53POLBMAPTTHRBLMNA | |
| SCHEMBL2172257 | 0.85 | TP53 (0.75) | TP53POLBMAPTTHRBLMNA | |
| SCHEMBL2171108 | 0.85 | MAPT (0.79) | TP53POLBMAPTTHRBLMNA | |
| SCHEMBL2549009 | 0.83 | POLB (0.68) | TP53POLBMAPTTHRBNR1H4 | |
| SCHEMBL2547296 | 0.82 | MAPT (0.69) | TP53POLBMAPTTHRBLMNA | |
| SCHEMBL2172534 | 0.82 | MAPT (0.68) | TP53POLBMAPTTHRBLMNA | |
| SCHEMBL2174259 | 0.82 | MAPT (0.62) | TP53POLBMAPTNR1H4 | |
| SCHEMBL2171479 | 0.81 | POLB (0.63) | TP53POLBMAPTTHRBLMNA | |
| SCHEMBL2540889 | 0.81 | MAPT (0.61) | TP53POLBMAPTTHRBLMNA | |
| SCHEMBL2547306 | 0.81 | MAPT (0.79) | TP53POLBMAPTTHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | TP53 4565/4885POLB 4360/4885MAPT 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.